Biohaven Ltd. (BHVN) - Total Liabilities
Based on the latest financial reports, Biohaven Ltd. (BHVN) has total liabilities worth $336.91 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Biohaven Ltd. liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Biohaven Ltd. - Total Liabilities Trend (2017–2025)
This chart illustrates how Biohaven Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Check BHVN asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Biohaven Ltd. Competitors by Total Liabilities
The table below lists competitors of Biohaven Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Array Digital Infrastructure, Inc.
NYSE:AD
|
USA | $2.10 Billion |
|
Central Garden & Pet Company A
NASDAQ:CENTA
|
USA | $2.09 Billion |
|
Sonos Inc
NASDAQ:SONO
|
USA | $455.12 Million |
|
SJW Group Common Stock
NYSE:SJW
|
USA | $3.33 Billion |
|
Uniti Group Inc
NASDAQ:UNIT
|
USA | $12.82 Billion |
|
Mayora Indah Tbk
JK:MYOR
|
Indonesia | Rp13.61 Trillion |
|
Generate Biomedicines, Inc. Common Stock
NASDAQ:GENB
|
USA | $105.64 Million |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥1.16 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Biohaven Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Biohaven Ltd. assets under control.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biohaven Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biohaven Ltd. (2017–2025)
The table below shows the annual total liabilities of Biohaven Ltd. from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $399.38 Million | +108.36% |
| 2024-12-31 | $191.67 Million | +124.87% |
| 2023-12-31 | $85.24 Million | -30.71% |
| 2022-12-31 | $123.01 Million | +159.68% |
| 2021-12-31 | $47.37 Million | +36.44% |
| 2020-12-31 | $34.72 Million | -90.13% |
| 2019-12-31 | $351.69 Million | +152.85% |
| 2018-12-31 | $139.09 Million | +832.44% |
| 2017-12-31 | $14.92 Million | -- |
About Biohaven Ltd.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase… Read more